Psoriasis

ABB071 is a humanized anti-CD180 monoclonal antibody. ABB071 can down-regulate the highly expressed TLR7 and IRF5 genes in systemic lupus erythematosus and induce the expression of PNPT1 and DNASE1L3 genes. ABB071 can inhibit the expression of genes related to the type I interferon pathway as well as interferon-stimulated genes (ISGs). ABB071 has anti-inflammatory activity and can reduce the levels of inflammatory cytokines. ABB071 can be used for research on systemic lupus erythematosus and psoriasis.

LY2775240 is an orally active phosphodiesterase 4 (PDE4) inhibitor with potent inhibitory activity against PDE4A (IC₅₀ = 0.09 nM), PDE4B (IC₅₀ = 0.09 nM) and PDE4D (IC₅₀ = 0.14 nM), and exhibits an IC₅₀ of 2.4 nM against PDE4C. LY2775240 is a highly selective agent that reduces TNFα production upon immune activation. LY2775240 decreases TNFα production in rodent and rhesus monkey models. LY2775240 can be used in the research of psoriasis.

TYK2 ligand 4 (Compound 2) is a TYK2 ligand. TYK2 ligand 4 binds to both the kinase domain and pseudokinase domain, and induces an inactive conformation of the kinase domain, thereby preventing ATP binding. TYK2 ligand 4 serves as a tool compound for the development of Deucravacitinib (HY-117287).

SM-15178 is a potent, orally active and selective leukotriene B₄ (LTB₄) receptor antagonist with an IC₅₀ of 0.30 μM. SM-15178 attenuates LTB₄ (HY-107608)-induced neutrophil accumulation in mouse skin and bronchoconstriction in guinea pigs. SM-15178 emonstrates significant anti-inflammatory efficacy across multiple animal models of inflammation. SM-15178 can be used for the research of chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, and asthma.

Lithocholic amide-C2-N(didecane) (Compound LC10) is a Lithocholic acid (HY-B0172) analogue. Lithocholic amide-C2-N(didecane) can form lipid nanoparticles spontaneously in the aqueous milieu, permeate through the skin, penetrate the deeper dermal layers, and exert anti-inflammatory effects against psoriasis-like chronic skin inflammations. Lithocholic amide-C2-N(didecane) can inhibit abnormal proliferation of keratinocytes, downregulate the mRNA expression of the psoriasis-associated receptor EphA2 and reduce serum levels of multiple pro-inflammatory factors such as IL-1α, IL-1β, and IFN-γ by inhibiting activation of the Th17/Th2 inflammatory pathway.

Tisocalcitate is a Vitamin D analogue, can be used for plaque type psoriasis research.

Revamilast (GRC 4039) is an orally active phosphodiesterase-4 (PDE4) inhibitor with an IC₅₀ of 3 nM. Revamilast inhibits the production of TNF-α. It can be used for research on rheumatoid arthritis, plaque psoriasis, asthma, and other inflammatory diseases.

Pegcantratinib (CT327) is a potent and selective TRKA antagonist with activity against TRKB and TRKC. Pegcantratinib can be used for research of CYLD cutaneous syndrome (CCS) and inflammatory dermatoses, such as psoriasis and concomitant pruritus.

VDR ligand-1 (compound 13a) is a nonsecosteroidal VDR agonist with an EC₅₀ value of 16 nM. VDR ligand-1 can be used for osteoporosis, psoriasis, and cancer research.

Butantrone is a derivative of Dithranol (HY-B0738) with antipsoriatic activity.

Bazlitoran (IMO-8400) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis.

Bazlitoran sodium (IMO-8400 sodium) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran sodium blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran sodium inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran sodium is associated with injection site reactions. Bazlitoran sodium improves moderate-to-severe plaque psoriasis.

(±)-Methotrexate-d₃ ((±)-Amethopterin-d₃; (±)-CL14377-d₃; (±)-WR19039-d₃) is the deuterated-labeled (±)-Methotrexate (HY-121151). (±)-Methotrexate is the racemate of Methotrexate (HY-14519). Methotrexate is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.

Enpatoran dihydrochloride (M5049 dihydrochloride) is an orally active and selective TLR7/8 antagonist. Enpatoran dihydrochloride inhibits the activation of the downstream type I interferon pathway. Enpatoran dihydrochloride is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis.

S101 is an inhibitor of SLP-76 and AhR. By inhibiting SLP-76 phosphorylation, S101 blocks the TCR signaling pathway and prevents AhR nuclear translocation, thereby selectively suppressing the proliferation of activated T cells, inducing their apoptosis, and reducing TNF-α levels. S101 can be used in studies of graft rejection, psoriasis, and superantigen-induced toxic shock.

JH-I-25 is an orally active IRAK1 and IRAK4 inhibitor. JH-I-25 inhibits LPS-induced IRAK4 phosphorylation, IRAK1 degradation, MAPK activation, and the expression of proinflammatory cytokines TNF-α and IL-6 in lung tissues. JH-I-25 improves the survival rate of LPS-induced septic mice and serves as an IRAK4 recruiter in the design of proteolysis-targeting chimeric molecules. JH-I-25 can be used in research related to diffuse large B-cell lymphoma, Waldenström's macroglobulinemia, septic shock, rheumatoid arthritis, atherosclerosis, Alzheimer's disease, acute lung injury, sepsis, and psoriasis.

Oxeclosporin is a cyclosporine prodrug with skin penetration properties. After penetrating rat skin, Oxeclosporin undergoes extensive cleavage and is converted to its active form, whereas only slight cleavage occurs in human skin. Oxeclosporin can be used in research on psoriasis, atopic dermatitis, and allergic contact dermatitis.

Rosin (Standard) is the analytical standard of Rosin (HY-N0508). This product is intended for research and analytical applications. Rosin is a natural oleoresin found in coniferous trees of the genus Pinus, such as Pinus massoniana. Rosin exhibits cholesterol-lowering, anti-gastric ulcer, anti-tumor, blood glucose-lowering, and anti-macrocyte aggregation activities. Rosin inhibits TPA (HY-18739)-induced EBV-EA activation and suppresses papilloma formation in a two-stage mouse skin carcinogenesis model. WBR, a processed product of Rosin, inhibits the IL-23/IL-17 inflammatory axis and reduces Th1 and Th17 cell infiltration. Rosin is used in research on psoriasis and skin cancer.

Fenoldopam mesylate (Standard) is the analytical standard of Fenoldopam mesylate (HY-B0735A). This product is intended for research and analytical applications. Fenoldopam (SKF-82526) mesylate is a selective dopamine D₁ receptor agonist. Fenoldopam mesylate binds to rat D₁B dopamine receptors (K_d = 11 nM) and human D₁A receptors (K_d = 17 nM) in COS-7 cell membranes expressing the cloned receptors. Fenoldopam mesylate modulates dopamine receptor expression, induces vasorelaxation in vascular tissues, reverses glomerular hyperfiltration in rat models, increases intracellular cAMP levels, promotes DARPP-32 phosphorylation in small cell lung cancer (SCLC) cells, inhibits cytokine secretion, and downregulates T cell activation markers in activated human T cells. Fenoldopam mesylate can be used for research on hypertension, acute kidney injury, psoriasis, and small cell lung cancer.

RORγt inverse agonist 38 (C102) is a RORγt inverse agonist. RORγt inverse agonist 38 can be used for the research of psoriasis, autoimmune thyroiditis, inflammatory bowel disease, cancer, and other conditions.